From July 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for HKD 0 million. With this, the company has completed the repurchase of 229,000 shares, representing 0.03% for HKD 0.21 million under the buyback announced on June 2, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 HKD | 0.00% | -1.67% | -13.87% |
May. 31 | Chinese Regulators Accept Fusen Pharmaceutical’s Drug Application | MT |
Apr. 04 | Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator | MT |
1st Jan change | Capi. | |
---|---|---|
-13.87% | 112M | |
+16.93% | 42.79B | |
+22.20% | 22.81B | |
+16.96% | 15.04B | |
+18.51% | 14.49B | |
+51.63% | 12.65B | |
-0.05% | 6.79B | |
-11.45% | 6.74B | |
-8.87% | 5.73B | |
+14.55% | 5.47B |
- Stock Market
- Equities
- 1652 Stock
- News Fusen Pharmaceutical Company Limited
- Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.